Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide

NCT02638805 on ClinicalTrials.gov · last registry update 2018-11-05

A small phase 3 — 136 participants, against a typical 424. The sponsor logged completion for October 2017. Primary outcome, as filed: Number (percentage) and severity of treatment-emergent adverse events (TEAEs) of nausea and/or vomiting. liraglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P3
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Intarcia Therapeutics
Sponsor type: Industry
Enrollment: 136
Started: 2015-12
Primary completion: 2017-10 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Number (percentage) and severity of treatment-emergent adverse events (TEAEs) of nausea and/or vomiting

Conditions studied

Diabetes Mellitus, Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.